Federated Hermes Inc. Has $4.66 Million Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Federated Hermes Inc. reduced its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 5.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 551,576 shares of the company’s stock after selling 32,309 shares during the quarter. Federated Hermes Inc. owned about 1.25% of Voyager Therapeutics worth $4,655,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Gladius Capital Management LP acquired a new stake in Voyager Therapeutics during the third quarter worth about $25,000. China Universal Asset Management Co. Ltd. acquired a new stake in Voyager Therapeutics during the fourth quarter worth about $43,000. Aigen Investment Management LP acquired a new stake in Voyager Therapeutics during the third quarter worth about $109,000. Ascension Capital Advisors Inc. acquired a new stake in Voyager Therapeutics during the third quarter worth about $112,000. Finally, Barclays PLC grew its position in Voyager Therapeutics by 188.8% during the third quarter. Barclays PLC now owns 18,309 shares of the company’s stock worth $141,000 after buying an additional 11,970 shares in the last quarter. 48.03% of the stock is owned by institutional investors and hedge funds.

Voyager Therapeutics Trading Up 2.7 %

NASDAQ:VYGR opened at $7.62 on Friday. Voyager Therapeutics, Inc. has a 1 year low of $6.06 and a 1 year high of $14.34. The firm has a 50 day moving average of $8.80 and a 200-day moving average of $7.96. The stock has a market capitalization of $413.77 million, a P/E ratio of 2.47 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. The company had revenue of $90.06 million during the quarter, compared to analysts’ expectations of $4.95 million. As a group, analysts forecast that Voyager Therapeutics, Inc. will post -1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VYGR has been the topic of a number of recent research reports. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. HC Wainwright started coverage on Voyager Therapeutics in a report on Tuesday, March 19th. They set a “buy” rating and a $30.00 price objective on the stock. Wells Fargo & Company raised Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $9.00 to $14.00 in a report on Tuesday, January 2nd. Citigroup started coverage on Voyager Therapeutics in a report on Thursday, March 7th. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Guggenheim started coverage on Voyager Therapeutics in a report on Tuesday, March 26th. They set a “buy” rating and a $22.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.